EveryONE Medicines, a company pioneering a scalable, global framework to design, develop, and manufacture individualized medicines for children with life-threatening neurodegenerative diseases, announced the appointment of Michelle L. Mellion, MD, as Chief Medical Officer. In this role, Dr. Mellion will lead the development and execution of the Company’s clinical trials, the first of which is expected to be initiated in the United Kingdom (UK) later this year and will include several types of genetically driven diseases. She will also oversee the establishment of EveryONE Medicines’ network of treatment centers globally, enabling the rapid expansion of the Company’s clinical pipeline.
“Dr. Mellion is joining at a pivotal moment as we prepare to launch a first-of-its-kind clinical trial in the UK later this year, which is a critical step in demonstrating a new, scalable approach to treating ultra-rare pediatric neurodegenerative diseases,” said Kent Rogers, chief executive officer of EveryONE Medicines. “Current regulatory pathways are not designed for truly individualized medicines, and Michelle’s deep expertise in navigating these complexities will be invaluable as we work to advance a more proportional framework. Her leadership will be instrumental as we expand our clinical efforts into the European Union and the United States in the future, ensuring more children have access to life-changing treatments.”
Also Read: Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
“EveryONE Medicines is redefining what’s possible for children with ultra-rare diseases by pioneering a sustainable approach to individualized medicine,” said Josh Ofman, MD, MSHS, and chairman of EveryONE Medicines. “Dr. Mellion’s expertise in neurology and her track record of industry leadership will be central to building the clinical infrastructure needed to efficiently develop, validate, and deliver these therapies at scale. Her guidance will not only accelerate our ability to bring life-changing medicines to more people living with ultra-rare diseases but also set the foundation for a future where no patient is left without options.”
“Throughout my career, I’ve witnessed the toll these diseases take on children and families and the limitations of a one-size-fits-all model,” said Dr. Mellion, chief medical officer of EveryONE Medicines. “With ASO therapies and advancements in individualized development pathways, we already have the tools needed to address these complex conditions. I’m proud to join this team to create a new paradigm shaping a new era of individualized treatment grounded in precision, compassion, and clinical excellence.”
SOURCE: Businesswire